SEC Comment Letter for Pluri Inc. (PLUR) (CIK 0001158780) (PLUR) — Jun 28, 2017
Pluri Inc. (PLUR) (CIK 0001158780)
Date: June 28, 2017 · CIK: 0001158780 · Accession: 0000000000-17-022677
AI Filing Summary & Sentiment
Reasoning
Letter
June 28, 2017 Zami Aberman Chairman and Co-Chief Executive Officer Pluristem Therapeutics Inc. MATAM Advanced Technology Park Buidling No. 5 Haifa L3 31905 Israel Pluristem Therapeutics Inc. Registration Statement on Form S-3 Filed June 23, 2017 File No. 333-218916Re: Dear Mr. Aberman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare and Insurance cc: Oded Har-Even, Esq.
Show Raw Text
June 28, 2017
Zami Aberman
Chairman and Co-Chief Executive Officer
Pluristem Therapeutics Inc.
MATAM Advanced Technology Park
Buidling No. 5
Haifa L3 31905 Israel
Pluristem Therapeutics Inc.
Registration Statement on Form S-3
Filed June 23, 2017
File No. 333-218916Re:
Dear Mr. Aberman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare and
Insurance
cc: Oded Har-Even, Esq.